...
ipha-img

Innate Pharma, Common Stock

IPHA

NSQ

$2.16

+$0.01

(0.47%)

1D
Industry: Biotechnology Sector: Health Care

Analyst Forecast

Price Chart

Key Metrics

Market Cap info-icon
This is a company’s total value as determined by the stock market. It is calculated by multiplying the total number of a company's outstanding shares by the current market price of one share.
$186.18M
P/E Ratio info-icon
This is the ratio of a security’s current share price to its earnings per share. This ratio determines the relative value of a company’s share.
0
Volume info-icon
This is the total number of shares traded during the most recent trading day.
156.44K
Avg Volume info-icon
This is the average number of shares traded during the most recent 30 days.
0
Dividend Yield info-icon
This ratio shows how much income you earn in dividend payouts per year for every dollar invested in the stock (or the stock’s annual dividend payment expressed as a percentage of its current price).
0.00%
Beta info-icon
This measures the expected move in a stock’s price relative to movements in the overall market. The market, such as the S&P 500 Index, has a beta of 1.0. If a stock has a Beta greater (or lower) than 1.0, it suggests that the stock is more (or less) volatile than the broader market.
0.87
52-week Range info-icon
This shows the range of the stock’s price between the 52-week high (the highest price of the stock for the past 52 weeks) and the 52-week low (the lowest price of the stock for the past 52 weeks).
$1.29 L
$3.51 H
$2.16

About Innate Pharma, Common Stock

Innate Pharma S.A., a biotechnology company, develops immunotherapies for cancer patients in France and internationally. The company's products include Lacutamab (IPH4102), an anti-KIR3DL2 antibody, which is in Phase II clinical trials for the treatment of cutaneous T-cell and peripheral T-cell lymphoma, as well as in Phase II clinical trials to treat refractory sézary syndrome; Monalizumab, an immune checkpoint inhibitor that is in Phase III clinical trial to treat advanced solid tumors comprising colorectal and lung cancer, as well as head and neck cancer; IPH5201, a blocking antibody that is in Phase II clinical trials targeting the CD39 immunosuppressive pathway; IPH5301, an anti-CD73 antibody targeting the immunosuppressive adenosine pathway to promote antitumor immunity; IPH6401, an BCMA-targeting NK cell engager; and IPH6101, a NKp46-based NK cell engager that targets CD123 proprietary multi-specific antibody format; and IPH62, an B7-H3-targeting NK cell engager. Its products in preclinical trials are IPH43, an anti-MICA/B ADC and IPH45, an antibody drug conjugates (ADC); and IPH67, an undisclosed, multi-specific ANKET. The company has licensing and collaboration agreements with AstraZeneca, Novo Nordisk A/S, Sanofi, and Orega Biotech; and co-development and license agreement with MedImmune Limited. Innate Pharma S.A. was incorporated in 1999 and is headquartered in Marseille, France. more

Industry: BiotechnologySector: Health Care

Returns

Time FrameIPHASectorS&P500
1-Week Return27.81%-2.06%-0.55%
1-Month Return41.18%-1.92%2.72%
3-Month Return-4%-10.4%7.66%
6-Month Return6.93%-4.6%10.15%
1-Year Return-11.84%4.06%27.53%
3-Year Return-56.97%1.94%32.31%
5-Year Return-65.11%36.48%89.2%
10-Year Return-64.3%97.46%194.59%

Financials

Dec '19Dec '20Dec '21Dec '22Dec '235YR TREND
Total Revenue68.97M56.83M12.11M49.64M51.90M[{"date":"2019-12-31","value":100,"profit":true},{"date":"2020-12-31","value":82.4,"profit":true},{"date":"2021-12-31","value":17.56,"profit":true},{"date":"2022-12-31","value":71.97,"profit":true},{"date":"2023-12-31","value":75.25,"profit":true}]
Cost of Revenue45.16M3.04M47.00M51.66M56.02M[{"date":"2019-12-31","value":80.61,"profit":true},{"date":"2020-12-31","value":5.43,"profit":true},{"date":"2021-12-31","value":83.9,"profit":true},{"date":"2022-12-31","value":92.22,"profit":true},{"date":"2023-12-31","value":100,"profit":true}]
Gross Profit23.82M53.79M(34.89M)(2.02M)(4.12M)[{"date":"2019-12-31","value":44.27,"profit":true},{"date":"2020-12-31","value":100,"profit":true},{"date":"2021-12-31","value":-64.87,"profit":false},{"date":"2022-12-31","value":-3.76,"profit":false},{"date":"2023-12-31","value":-7.66,"profit":false}]
Gross Margin34.53%94.65%(288.08%)(4.08%)(7.94%)[{"date":"2019-12-31","value":36.48,"profit":true},{"date":"2020-12-31","value":100,"profit":true},{"date":"2021-12-31","value":-304.37,"profit":false},{"date":"2022-12-31","value":-4.31,"profit":false},{"date":"2023-12-31","value":-8.39,"profit":false}]
Operating Expenses50.87M75.38M59.94M66.06M64.57M[{"date":"2019-12-31","value":67.48,"profit":true},{"date":"2020-12-31","value":100,"profit":true},{"date":"2021-12-31","value":79.51,"profit":true},{"date":"2022-12-31","value":87.64,"profit":true},{"date":"2023-12-31","value":85.66,"profit":true}]
Operating Income(27.05M)(13.69M)(47.83M)(11.65M)(12.67M)[{"date":"2019-12-31","value":-2705300000,"profit":false},{"date":"2020-12-31","value":-1369200000,"profit":false},{"date":"2021-12-31","value":-4782500000,"profit":false},{"date":"2022-12-31","value":-1165100000,"profit":false},{"date":"2023-12-31","value":-1266900000,"profit":false}]
Total Non-Operating Income/Expense7.73M(17.43M)4.69M(1.09M)7.64M[{"date":"2019-12-31","value":100,"profit":true},{"date":"2020-12-31","value":-225.62,"profit":false},{"date":"2021-12-31","value":60.75,"profit":true},{"date":"2022-12-31","value":-14.15,"profit":false},{"date":"2023-12-31","value":98.82,"profit":true}]
Pre-Tax Income(20.76M)(63.98M)(45.48M)(57.97M)(7.57M)[{"date":"2019-12-31","value":-2075900000,"profit":false},{"date":"2020-12-31","value":-6398400000,"profit":false},{"date":"2021-12-31","value":-4547800000,"profit":false},{"date":"2022-12-31","value":-5797200000,"profit":false},{"date":"2023-12-31","value":-757000000,"profit":false}]
Income Taxes206.00K6.76M13.66M41.13M(9.73M)[{"date":"2019-12-31","value":0.5,"profit":true},{"date":"2020-12-31","value":16.44,"profit":true},{"date":"2021-12-31","value":33.21,"profit":true},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":-23.65,"profit":false}]
Income After Taxes(20.96M)(70.75M)(59.14M)(99.10M)2.16M[{"date":"2019-12-31","value":-971.05,"profit":false},{"date":"2020-12-31","value":-3276.84,"profit":false},{"date":"2021-12-31","value":-2739.05,"profit":false},{"date":"2022-12-31","value":-4590.23,"profit":false},{"date":"2023-12-31","value":100,"profit":true}]
Income From Continuous Operations(20.76M)(63.98M)(45.48M)(57.97M)(7.57M)[{"date":"2019-12-31","value":-2075900000,"profit":false},{"date":"2020-12-31","value":-6398400000,"profit":false},{"date":"2021-12-31","value":-4547800000,"profit":false},{"date":"2022-12-31","value":-5797200000,"profit":false},{"date":"2023-12-31","value":-757000000,"profit":false}]
Income From Discontinued Operations(7.33M)(7.33M)(7.33M)(131.00K)-[{"date":"2019-12-31","value":-733100000,"profit":false},{"date":"2020-12-31","value":-733100000,"profit":false},{"date":"2021-12-31","value":-733100000,"profit":false},{"date":"2022-12-31","value":-13100000,"profit":false},{"date":"2023-12-31","value":"-","profit":true}]
Net Income(20.96M)(70.75M)(59.14M)(99.10M)(7.57M)[{"date":"2019-12-31","value":-2096500000,"profit":false},{"date":"2020-12-31","value":-7074700000,"profit":false},{"date":"2021-12-31","value":-5913600000,"profit":false},{"date":"2022-12-31","value":-9910300000,"profit":false},{"date":"2023-12-31","value":-757000000,"profit":false}]
EPS (Diluted)(0.14)(0.43)(0.84)-0.02[{"date":"2019-12-31","value":-724,"profit":false},{"date":"2020-12-31","value":-2134,"profit":false},{"date":"2021-12-31","value":-4190,"profit":false},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":100,"profit":true}]

Ratios

Liquidity

These ratios help you determine the liquidity of the company. Higher is better.

IPHA
Cash Ratio 2.40
Current Ratio 2.92
Quick Ratio 2.84

Asset Efficiency

These ratios help you understand the company's efficiency in using its assets to generate returns. Higher is better. For ROE, average long term is around 14%, less than 10% is poor.

IPHA
ROA (LTM) -13.76%
ROE (LTM) -78.59%

Liabilities

These ratios help you understand the company's liabilities, gauging the riskiness of the investment.

IPHA
Debt Ratio Lower is generally better. Negative is bad. 0.81
Common Equity/Total Assets Higher is better. Lower can suggest investment is riskier. 0.19

Valuation

These ratios help you understand the company's valuation. Lower may indicate cheaper stocks.

IPHA
Trailing PE NM
Forward PE NM
P/S (TTM) 5.29
P/B 5.89
Price/FCF 130
EV/R 4.55
EV/Ebitda NM

FAQs

What is Innate Pharma share price today?

Innate Pharma (IPHA) share price today is $2.16

Can Indians buy Innate Pharma shares?

Yes, Indians can buy shares of Innate Pharma (IPHA) on Vested. To buy Innate Pharma from India, you can open a US Brokerage account on Vested today by clicking on Sign Up or Invest in IPHA stock at the top of this page. The account opening process is completely digital and secure, and takes a few minutes to complete.

Can Fractional shares of Innate Pharma be purchased?

Yes, you can purchase fractional shares of Innate Pharma (IPHA) via the Vested app. You can start investing in Innate Pharma (IPHA) with a minimum investment of $1.

How to invest in Innate Pharma shares from India?

You can invest in shares of Innate Pharma (IPHA) via Vested in three simple steps:

  • Click on Sign Up or Invest in IPHA stock at the top of this page
  • Breeze through our fully digital and secure KYC process and open your US Brokerage account in a few minutes
  • Transfer USD funds to your US Brokerage account and start investing in Innate Pharma shares
What is Innate Pharma 52-week high and low stock price?

The 52-week high price of Innate Pharma (IPHA) is $3.51. The 52-week low price of Innate Pharma (IPHA) is $1.29.

What is Innate Pharma price-to-earnings (P/E) ratio?

The price-to-earnings (P/E) ratio of Innate Pharma (IPHA) is

What is Innate Pharma price-to-book (P/B) ratio?

The price-to-book (P/B) ratio of Innate Pharma (IPHA) is 5.89

What is Innate Pharma dividend yield?

The dividend yield of Innate Pharma (IPHA) is 0.00%

What is the Market Cap of Innate Pharma?

The market capitalization of Innate Pharma (IPHA) is $186.18M

What is Innate Pharma’s stock symbol?

The stock symbol (or ticker) of Innate Pharma is IPHA

Signup to access all features and start your US investing journey!

  • Open your account in minutes
  • Take your portfolio global, starting at just $1
Get started

Add ticker to compare

Scroll to Top